Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →
logo
Get CLEATUSFree Trial

Infinium Global Diversity Array Kits.

Active
75N98026Q00671Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

Illumina, Inc. is the sole manufacturer of the Infinium Global Diversity Array Kits and is the only provider capable of delivering specialized technical support for these arrays and associated reagents. In the event of assay failure, Illumina’s dedicated team of technical applications scientists and field application scientists, who possess deep expertise in the assay system, will troubleshoot issues and, when necessary, provide replacement reagents at no cost. This level of specialized, manufacturer-backed support is unmatched by any other provider and is critical to ensuring assay reliability and research continuity. The solicitation, numbered 75N98026Q00671, issued by the National Institutes of Health under the Department of Health and Human Services, seeks procurement of these kits with a response deadline of July 2, 2026, and is managed by the office located in Bethesda, Maryland.

General Info

Illumina exclusively provides Infinium arrays with free troubleshooting and replacements; NIH seeks procurement by July 2, 2026.

Agency

Department Of Health And Human Services → National Institutes Of Health OlaoView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

(1)

Presolicitation Notice 75N98026Q00671 for Infinium Global Diversity Array Kits

DOCX•presolicitation

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

PhasePresolicitation
Posted

Presolicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao
Contacts1 person available
OfficeBETHESDA, MD, 20892, USA
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health Olao
View Agency Profile
Office AddressBETHESDA, MD, 20892, USA
Contacts
Vishnuvajjala Hanumanth Rao
contact@example.gov

Full Description

Show more

As the manufacturer of the Infinium Methylation Global Diversity Array, Illumina, Inc is uniquely situated to provide technical support for the arrays and reagents in the case of assay failure. The Illumina product support service team includes highly qualified technical applications scientists (TAS), and field application scientists (FAS) and others that are deeply familiar with the intricacies of the assay system and are able to troubleshoot and provide replacement reagents FOC if necessary. NO other provider is able to provide this level of support for the arrays

Similar Contracts

NAICS: 541714
New
SLED
Bioinformatics Analysis & Data InterpretationThis contract solicits computational analysis of genomic data through bioinformatics pipelines, focusing on variant calling, annotation, and the generation of clinical reports. The work requires specialized expertise in processing large-scale genomic datasets to identify and interpret genetic variants with clinical relevance, ensuring accurate and actionable results. The project is structured as a subcontract under the NAICS code 541714, which corresponds to scientific research and development in the life sciences. The opportunity was posted on June 18, 2026, with a deadline for responses set for July 8, 2026. It is issued by the state of Utah, with no specified office address or point of contact details, and no set-aside classification is indicated. The performance location is not defined, and the opportunity is accessible via a public portal link hosted on Bonfire Hub.
Utah

POSTED

5 days ago

DEADLINE

in 16 days
View Details
NAICS: 541714
New
Grant
Discovery of the Genetic Basis of Childhood Cancers and of Congenital Anomalies: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)The National Institutes of Health, through the Gabriella Miller Kids First Pediatric Research Program, is inviting applications to submit pediatric samples for advanced genomic and molecular analyses aimed at uncovering the genetic foundations of childhood cancers and congenital anomalies. Applicants are encouraged to propose sequencing of existing pediatric cohorts to investigate somatic and germline genetic contributions to these conditions, explore the molecular links between congenital anomalies and elevated cancer risk, or broaden the spectrum of pediatric disorders represented in the Kids First Data Resource. The program supports a wide range of technologies including whole genome, exome, and transcriptome sequencing, as well as clinical-grade sequencing, long-read sequencing, proteomics, and epigenomic assays on tumor or affected tissues, provided the scientific rationale is strong. There is a specific emphasis on expanding representation of populations already included in existing Kids First projects to enhance the diversity and utility of the data. All generated data, along with associated clinical and phenotypic information, will be deposited into the Kids First Data Resource Center, making it openly available to the broader research community to accelerate discoveries in pediatric health. This opportunity is issued under solicitation PAR-27-071, with a submission deadline of January 11, 2027, and is not open for clinical trials. Applications must be submitted through Grants.gov, and inquiries can be directed to the designated point of contact at the NIH. The initiative is part of a larger federal effort under the U.S. Department of Health and Human Services to advance pediatric research through open data sharing and cutting-edge genomic technologies.
National Institutes Of Health

POSTED

5 days ago

DEADLINE

in 7 months
View Details
NAICS: 541714
New
Grant
Limited Competition: Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) (P30 - Clinical Trial Not Allowed)The Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) is a limited competition funding opportunity issued by the National Institutes of Health under PAR-27-055 to strengthen biomedical research capacity at institutions in states historically underserved by NIH funding. This initiative supports IDeA-eligible institutions in expanding their research infrastructure through COBRE-E, which focuses on growing the faculty base and establishing new research projects and core facilities in strategically important scientific areas, and sustaining these gains through COBRE-S, which aims to consolidate research cores and further develop institutional research excellence. Applications must demonstrate a clear pathway to long-term self-sufficiency and alignment with the institution’s research priorities, with clinical trials explicitly prohibited under this P30 award mechanism. The solicitation is open only to eligible organizations that have previously received COBRE funding and are positioned to advance to the expansion or sustainability phase. The opportunity is governed by standard NIH peer-review procedures, with funding decisions based solely on scientific merit. Applications must be submitted by the deadline of May 25, 2029, and institutions interested in applying should reference the official NIH Grants.gov page for detailed eligibility criteria and submission guidelines. Questions regarding the program can be directed to the designated NIH point of contact through email or phone.
National Institutes Of Health

POSTED

5 days ago

DEADLINE

in almost 3 years
View Details
NAICS: 541714
New
Grant
GREGoRi Innovation Projects (U01 Clinical Trial Optional)The GREGoRi Innovation Projects initiative, funded by the National Institutes of Health under the Department of Health and Human Services, aims to revolutionize the diagnosis of rare genetic diseases by supporting highly innovative experimental and computational approaches that go beyond current methodologies. This funding opportunity encourages the development and rigorous testing of novel tools, molecular technologies, and analytical frameworks capable of identifying causal genes or variants in rare disorders with transformative speed and accuracy. The program seeks proposals that challenge existing paradigms in rare disease genomics, prioritizing groundbreaking ideas with the potential to significantly improve diagnostic outcomes and expand understanding of genetic mechanisms. Applicants must submit proposals by the deadline of October 30, 2026, through the solicitation number RFA-HG-27-013, which is structured as a U01 award with clinical trials being optional. The initiative is open to federal and non-federal entities without set-asides, and funding recipients are expected to operate across the United States with no specific geographic restrictions. All inquiries should be directed to the designated point of contact at nhgri-gregor@mail.nih.gov or by phone at 301-402-2541. Further details and the official application portal are accessible via the provided grants.gov link.
National Institutes Of Health

POSTED

5 days ago

DEADLINE

in 4 months
View Details
NAICS: 541714
New
Grant
Biotechnology Risk Assessment Research Grants ProgramThe Biotechnology Risk Assessment Research Grants Program, funded by the National Institute of Food and Agriculture under Assistance Listing 10.219, supports research to generate scientific information that informs federal regulatory decisions regarding the ecological risks of genetically engineered organisms produced through recombinant, synthesized, or amplified nucleic acid techniques. This includes a broad range of organisms such as plants, microorganisms, arthropods, fish, birds, livestock, and other animals—both wild and agricultural—with the goal of assessing hazard identification, probability of occurrence, severity and extent of effects, and comparison to unmodified organisms. The program seeks to advance environmental risk assessment and risk management research, particularly in areas like gene drives, large-scale cultivation of GE plants (100+ acres), gene flow, dispersal effects, and deployment strategies. Applications must be submitted electronically via Grants.gov by the deadline of July 13, 2026, and are evaluated through a two-part process beginning with administrative screening followed by a peer-review assessment. Applications are scored based on four equally weighted criteria: scientific merit, personnel and facilities, budget justification, and, for workshop proposals, relevance and dissemination. Awards are made for periods of up to four years, with individual funding ranging from $10,000 to $650,000 for standard research proposals and up to $50,000 for workshops, under a total program budget of $5 million. Indirect costs are capped at 30% of total federal funds awarded, and subawards cannot exceed 50% of the award without prior approval. Awardees must comply with NIFA’s General Awards Administrative Provisions, USDA’s regulations under 2 CFR Chapter IV, and the OMB Uniform Guidance, with all changes to scope, key personnel, or budget requiring prior written approval. Applicants must also submit required certifications through Grants.gov forms, provide a detailed project timetable covering the entire duration including post-funding phases, and ensure all submissions comply with PDF formatting, 12-point font, one-inch margins, and letter-sized pages. A letter of intent is encouraged but not required for standard grants and must be submitted by July 1, 2026. Only applicants who meet administrative requirements advance to technical review, and highly meritorious applicants who request Centers of Excellence consideration may receive prioritization in award decisions, even if they do not fully meet all COE standards.
National Institute Of Food And Agriculture

POSTED

5 days ago

DEADLINE

in 21 days
View Details